Treatment approaches to nasopharyngeal carcinoma: A review

Anti-Cancer Drugs

Volumn 21, Issue 5, 2010, Pages 471-477

  Caponigro, Francesco ^a   Longo, Francesco ^a   Ionna, Franco ^a   Perri, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adjuvant chemotherapy; Concomitant chemoradiotherapy; Epstein Barr virus; Nasopharyngeal carcinoma; Neoadjuvant chemotherapy; Radiotherapy

Indexed keywords

BLEOMYCIN; CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; PACLITAXEL; PLATINUM; VIRUS DNA;

ADVANCED CANCER; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CYTOTOXIC T LYMPHOCYTE; DISTANT METASTASIS; EARLY CANCER; EPSTEIN BARR VIRUS; GENE OVEREXPRESSION; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW;

CARCINOMA; COMBINED MODALITY THERAPY; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY; NASOPHARYNGEAL NEOPLASMS; NEOADJUVANT THERAPY;

EID: 77951273802     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328337160e     Document Type: Review

References (64)

1. Brennan B. Nasopharyngeal carcinoma. Orphanet J Rare Dis 2006; 1:23.
2. Takeshita H, Furukawa M, Fujieda S, Shoujaku H, Ookura T, Sakaguchi M, et al. Epidemiological research into nasopharyngeal carcinoma in the Chubu region of Japan. Auris Nasus Larynx 1999; 26:277-286.
3. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal cancer. Cancer Treat Res 2003; 114:275-293.
4. WangCC. Radiation therapy for head and neck neoplasms. 3rd ed. New York: Wiley-Liss; 1997. p. 274.
5. Song CH, Wu HG, Heo DS, Kim KH, Sung MW, Park CI. Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma. Laryngoscope 2008; 118:663-670.
6. Ma BB, Mo FK, Chan AT, Hui E, Leung S, Lo Y, et al. The prognostic significance of tumor vascular invasion and its association with plasma Epstein-Barr virus DNA, tumor volume and metabolic activity in locoregionally advanced nasopharyngeal carcinoma. Oral Oncol 2008; 44:1067-1072.
7. Ho HC, Lee MS, Hsiao SH, Hwang JH, Hung SK, Lee CC, et al. Prognostic influence of parapharyngeal extension in nasopharyngeal carcinoma. Acta Otolaryngol 2008; 128:790-798.
8. Xiao GL, Gao L, Xu GZ. Prognostic influence of parapharyngeal space involvement in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2002; 52:957-963.
9. Cheng SH, Tsai SY, Yen KL, Jian J, Feng A, Chan K, et al. Prognostic significance of parapharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I-III nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2005; 61:456-465.
10. Liu MT, Hsieh CY, Chang TH, Lin JP, Huang CC, Wang AY. Prognostic factors affecting the outcome of nasopharyngeal carcinoma. Jpn J Clin Oncol 2003; 33:501-508.
11. Chua DT, Sham JS, Leung LH, Tai KS, Au GK. Tumor volume is not an independent prognostic factor in early-stage nasopharyngeal carcinoma treated by radiotherapy alone. Int J Radiat Oncol Biol Phys 2004; 58:1437-1444.
12. Leung TW, Wong VY, Sze WK, Lui CM, Tung SY. High-dose rate intracavitary brachytherapy boost for early T stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2008; 70:361-367.
13. Lin SJ, Pan JJ, Wu JX, Han L, Pan CZ. Long-term efficacy of external radiotherapy plus intracavitary hyperfractionated brachytherapy on nasopharyngeal carcinoma. Ai Zheng 2007; 26:208-211.
14. Cao XP, Lu TX, Ye WJ, Cui NJ. Prospective study on long-term efficacy of external plus intracavitary radiotherapy on stage I-II nasopharyngeal carcinoma. Ai Zheng 2007; 26:204-207.
15. Lu JJ, Shakespeare TP, Tan LK, Goh BC, Cooper JS. Adjuvant fractionated high-dose rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma. Head Neck 2004; 26:389-395.
16. Leung TW, Tung SY, Wong VWY, Sze WK, Lui CMM, Wong FCS, et al. Nasopharyngeal intracavitary brachytherapy: the controversy of T2b disease. Cancer 2005; 104:1648-1655.
17. Chen MY, Cao XP, Sun R, Hua YJ, Li AJ, Liu YY, et al. Application of interstitial brachytherapy via parapharynx involvement transnasal approach to enhance dose in radiotherapy for nasopharyngeal carcinoma. Ai Zheng 2007; 26:513-518.
18. Pow EH, Kwong DL, McMillan AS,Wong MCM, Sham JST, Leung LHT, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006; 66:981-991.
19. Fang FM, TsaiWL, Chen HC, Hsu HC, Hsiung CY, Chien CY, et al. Intensitymodulated or conformal radiotherapy improves the quality of life of patients with nasopharyngeal carcinoma: comparisons of four radiotherapy techniques. Cancer 2007; 109:313-321.
20. Kwong DL, Pow EH, Sham JS, Mcmillan AS, Leung LHT, Leung WK, et al. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Cancer 2004; 101:1584-1593.
21. Sultanem K, Shu HK, Xia P, Akazawa C, Quivey JM, Verhey LJ, et al. Threedimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2000; 48:711-722.
22. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS,Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003; 21:631-637.
23. Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002; 20:2038-2044.
24. Chen Y, Liu MZ, Liang SB, Zong J, Mao Y, Tang L, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys 2008; 71:1356-1364.
25. Lu H, Peng L, Yuan X, Hao Y, Lu Z, Chen J, et al. Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a treatment paradigm also applicable to patients in Southeast Asia. Cancer Treat Rev 2009; 35:345-353.
26. Zhang L, Zhao C, Ghimire BR, Guo Y, Guan ZZ. The role of concurrent chemoradiation in the treatment of locally advanced nasopharyngeal carcinoma among endemic area: a meta-analysis of the phase III randomized trial. J Clin Oncol 2008; 26:6032.
27. He XY, Hu CS, Ying HM, Wu YR, Zhu GP, Liu TF. Paclitaxel with cisplatin in concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol 2009. doi: 10.1007/s00405-009-1112-7.
28. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16:1310-1317.
29. Wee J, Tan EH, Tai BC,Wong HB, Leong SS, Tan T, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/ International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005; 23:6730-6738.
30. Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001; 19:1350-1357.
31. Al-Amro A, Al-Rajhi N, Khafaga Y, Memon M, Al-Hebshi A, El-Enbabi A, et al. Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2005; 62:508-513.
32. Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009; 27:242-249.
33. Yamouni M, Benhadji KA, Beldjilali Y, Lahfa I, Khellafi H, Abdelaoui A, et al. Phase II trial of combination docetaxel and cisplatin in patients with locally advanced nasopharyngeal carcinoma [abstract 6044]. J Clin Oncol 2009; 27.
34. Bossi P, Parolini D, Bergamini C, Locati LD, Orlandi E, Franceschini M, et al. TPF induction chemotherapy (CT) followed by concomitant cisplatin/ radiotherapy (cCTRT) in locally advanced nasopharyngeal cancer (LANPC) [abstract 6046]. J Clin Oncol 2009; 27.
35. Cho S, Bae W, Hwang J, Shim H, Lee J, Lim S, et al. Phase II study of docetaxel, cisplatin and 5-FU induction chemotherapy followed by concurrent chemoradiotherapy for advanced nasopharyngeal cancer [abstract 17010]. J Clin Oncol 2008; 26.
36. Beldjilali Y, Benhadji KA, Boukerche A, Khellafi H, Abdelaoui A, Betkaoui F, et al. First results of induction chemotherapy with cisplatin, docetaxel, and capecitabine for the treatment of nasopharyngeal carcinoma [abstract 6045]. J Clin Oncol 2009; 27.
37. Ferrari D, Chiesa F, Codè ca C, Calabrese L, Jereczek-Fossac BA, Alterio D, et al. Locoregionally advanced nasopharyngeal carcinoma: induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin: a phase II study. Oncology 2008; 74:158-166.
38. Chua D, Ng W, Yiu H, Seetalarom K, Kurnianda J, Sze W, et al. Phase II trial of first-line capecitabine plus cisplatin in patients with advanced/ metastatic nasopharyngeal cancer (NPC) [abstract 6033]. J Clin Oncol 2008; 26.
39. Airoldi M, Pedani F, Marchionatti S, Gabriele AM, Succo G, Gabriele P, et al. Carboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma. Tumori 2002; 88:273-276.
40. Ngeow JY, Gao F, Leong SS, LimW, Toh C, Tan EH. Phase II study of weekly docetaxel as salvage therapy for disseminated nasopharyngeal carcinoma [abstract 6057]. J Clin Oncol 2008; 26.
41. Chua D, Wei WI, Sharm JS, Au GK. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer. Jpn J Clin Oncol 2008; 38:244-249.
42. Chan ATC, Hsu MM, Goh BC, Hui EP, Liu TW, Millward MJ, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005; 23:3568-3576.
43. Chua DT,Wei WI,Wong MP, Sham JS, Nicholls J, Au GK. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head and Neck 2008; 30:863-867.
44. Elser C, Siu LL,Winquist E, Agulnik M, Pond GR, Chin SF, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25:3766-3773.
45. Yeo W, Goh B, Le Tourneau C, Green SR, Chiao JH, Siu LL. A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma [abstract 6026]. J Clin Oncol 2009; 27.
46. Masmoudi A, Toumi N, Khanfir A, Kallel-Slimi L, Daoud J, Karray H, et al. Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma. Cancer Treat Rev 2007; 33:499-505.
47. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004; 10:803-821.
48. Straathof KC, Bollard CM, Rooney CM, Heslop HE. Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist 2003; 8:83-98.
49. Khanna R, Tellam J, Duraiswamy J, Cooper L. Immunotherapeutic strategies for EBV-associated malignancies. Trends Mol Med 2001; 7:270-276.
50. Lin JC,Wang JY, Chen KY,Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350:2461-2470.
51. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15:405-431.
52. Moss DJ, Burrows SR, Khanna R, Misko IS, Sculley TB. Immune surveillance against Epstein-Barr virus. Semin Immunol 1992; 4:97-104.
53. Chang KL, Chen YY, Shibata D, Weiss LM. Description of an in situ hybridization methodology for detection of Epstein-Barr virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues. Diagn Mol Pathol 1992; 1:246-255.
54. Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol 1995; 146:1355-1367.
55. Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992; 66:2689-2697.
56. Khanna R, Busson P, Burrows SR, Raffoux C, Moss DJ, Nicholls JM, et al. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res 1998; 58:310-314.
57. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992; 176: 157-168.
58. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 2005; 23:8942-8949.
59. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus specific T lymphocytes. Blood 2005; 105:1898-1904.
60. Wirth LJ, Fogg M,Wang F, Lork J, Haddad RI, Posner MR. Epstein Barr virus (EBV)-specific immunotherapy in nasopharyngeal carcinoma (NPC) [abstract 6025]. J Clin Oncol 2009.
61. Lin CL, Lo WF, Lee TH, Ren Y, Hwang SL, Cheng YF, et al. Immunization with Epstein-Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8 + T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002; 62:6952-6958.
62. Duraiswamy J, Sherritt M, Thomson S, Tellam J, Cooper L, Connolly G, et al. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 2003; 101:3150-3156.
63. Feng WH, Israel B, Raab-Traub N, Busson P, Kenney SC. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBVpositive epithelial cell tumors. Cancer Res 2002; 62:1920-1926.
64. Westphal EM, Blackstock W, Feng W, Israel B, Kenney SC. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res 2000; 60:5781-5788.